Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Completed · Phase 3 · Has a placebo group

Conditions studied: Metastatic, Uveal Melanoma

In brief

Selumetinib therapy in patients with metastatic uveal melanoma.

Key facts

Study ID

NCT01974752

Run by

AstraZeneca

People needed

152

Starts

2014-04-01

Expected to finish

2016-10-01

Last updated by the study team

2017-01-05

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Aurora, Colorado, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Lutherville, Maryland, United States
• Research Site — St Louis, Missouri, United States
• Research Site — New York, New York, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Edegem, Belgium
• Research Site — Ghent, Belgium
• Research Site — Kortrijk, Belgium
• Research Site — Leuven, Belgium
• Research Site — Toronto, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Olomouc, Czechia
• Research Site — Prague, Czechia
• Research Site — Hus, Finland
• Research Site — Nice, France
• Research Site — Paris, France
• Research Site — Heidelberg, Germany
• Research Site — München, Germany
• Research Site — Jerusalem, Israel
• Research Site — Ramat Gan, Israel
• Research Site — Leiden, Netherlands
• Research Site — Barcelona, Spain
• Research Site — L'Hospitalet de Llobregat, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.